サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：キャッスルマン病治療の世界市場-2022-2029
市場調査レポート
商品コード
1004982

キャッスルマン病治療の世界市場-2022-2029

Global Castleman Disease Treatment Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
キャッスルマン病治療の世界市場-2022-2029
出版日: 2022年06月03日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

研究機関が実施するキャッスルマン病治療のための臨床試験が、市場成長の原動力になると予想されます。

Castleman Disease Collaborative Network（CDCN）は、ペンシルバニア大学およびアーカンソー大学医学部と提携し、抗IL-6療法に反応しない特発性多中心性キャッスルマン病（iMCD）の成人を対象に、治験薬シロリムスの試験を実施しています。シルトキシマブ（シルバント）とトシリズマブは、抗IL-6薬（アクテムラ）の2剤です。さらに、中国北京の北京ユニオン医科大学病院では、ボルテゾミブ、シクロホスファミド、デキサメタゾン（BCDレジメン）の有効性と安全性を検証する臨床試験への参加者を募集しています。このように、上記の記述から予測期間において市場が牽引されることが予想されます。

抑制要因

本疾患の有病率が低いこと、また本疾患に関する知識が不足していることから、認知度が低いです。治療費の高騰や複数の企業の特許切れなどが、予測期間中に市場が阻害される要因として予想されています。

COVID-19の影響分析

COVID-19のパンデミックは、ヘルスケアシステムと市場に中程度の影響を及ぼしています。シルトキシマブやトシリズマブなどの抗IL6薬は、一部の重症患者におけるCOVID-19誘発性のサイトカインストームの治療にも使用されています。さらに、シルトキシマブやトシリズマブなどの抗IL6薬は、特発性多中心性キャッスルマン病の一部の患者さんに対する有効な治療法として現在確立しています。これらの薬剤は短期的に症状を緩和しますが、安全性も高く、反応した人には長期的に病気をコントロールすることができます。COVID-19のパンデミックの際、CDCNはシルトキシマブとトシリズマブの供給不足を理解しています。CDCNは、キャッスルマン病患者にとって重要なこれらの医薬品の入手可能性について懸念しています。CDCNは、シルトキシマブとトシリズマブの生産者がキャッスルマン病患者に薬剤を提供することを約束していることを知りました。そのため、多くの企業は、製品の入手可能性を確保し、サプライチェーンを保護するために、他の地域へと変化していきます。このように、市場は影響を受けていますが、経済活動の再開に伴い、急速に牽引していくことが期待されます。

世界の城主病治療市場レポートでは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • タイプ別市場内訳
  • 診断別市場内訳
  • 治療法別市場内訳
  • エンドユーザー別市場内訳
  • 市場内訳：流通チャネル別
  • 地域別市場内訳

第4章 市場力学

  • 市場インパクトファクター
    • 促進要因
      • 研究機関別キャッスルマン病治療のための臨床試験が、市場成長の原動力になると予想されます。
    • Restraints（阻害要因
      • 治療費の高騰が市場成長を阻害すると予想されます。
    • 機会
    • 影響分析

第5章 産業分析

  • サプライチェーン分析
  • 価格設定分析
  • アンメットニーズ分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 タイプ別

  • 単核性キャッスルマン病
  • 多中心性キャッスルマン病

第8章 診断別

  • 血液検査・尿検査
  • 画像検査
    • X線検査
    • CTスキャン
    • その他
  • リンパ節生検
  • その他

第9章 治療法別

  • 免疫療法
    • シルトキシマブ（シルバント）
    • リツキシマブ（リツキサン）
    • その他
  • 化学療法
  • 副腎皮質ステロイド
    • プレドニゾン
    • トシリズマブ
    • レナリドマイド
    • グルココルチコイド
    • その他
  • 抗ウイルス剤
    • ガンシクロビル
    • その他

第10章 エンドユーザー別

  • 病院
  • クリニック
  • 外来手術センター
  • 診断センター
  • その他

第11章 流通チャネル別

  • 病院内薬局
  • 小売薬局
  • オンライン薬局
  • その他

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第13章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第14章 企業プロファイル

  • EUSA Pharma
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Johnson & Johnson Services, Inc.
  • Genentech USA, Inc.
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Par Pharmaceutical
  • Exela Pharma Sciences

第15章 キャッスルマン病治療の世界市場-DataM

目次
Product Code: DMPH3381

Market Overview

The Global Castleman Disease Treatment Market is expected to grow at a high CAGR during the forecasting period (2022-2029).

Castleman disease is a rare disorder in which cells in the lymph nodes grow out of control. The most prevalent form of the disorder (unicentric Castleman disease) involves a single lymph node in the chest or belly. Depending on the patient's type of Castleman disease, treatment and prognosis will differ. Surgery is frequently successful in treating the type that involves only one lymph node.

Market Dynamics

Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.

The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Moreover, The Peking Union Medical College Hospital in Beijing, China, sought participants for a clinical trial examining the efficacy and safety of the drugs bortezomib, cyclophosphamide, and dexamethasone (BCD regimen). Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Due to the disease's low prevalence rate and a lack of knowledge about it, there is a lack of awareness. The Patent expiry of several companies associated with the high cost of treatment are factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Anti-IL6 drugs like siltuximab and tocilizumab are also being used to treat COVID-19-induced cytokine storms in some critically ill patients. Moreover, Anti-IL6 medicines like siltuximab and tocilizumab are now well-established as viable treatments for some individuals with idiopathic multicentric Castleman disease. These drugs alleviate symptoms in the short term, but they are also safe and provide long-term disease control in responders. During the COVID-19 pandemic, the CDCN understands a supply shortfall of siltuximab and tocilizumab. The CDCN is concerned about the availability of these important medications for Castleman Disease patients. The CDCN learned that the producers of siltuximab and tocilizumab are committed to providing the drugs to individuals with Castleman Disease. Therefore, many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Immunotherapy segment is expected to hold the largest market share in castleman disease treatment market

The immunotherapy segment is expected to dominate in 2021. The segment is benefitted because drugs like siltuximab (Sylvant) and rituximab (Rituxan) can inhibit the function of a protein that is overproduced in persons with multicentric Castleman disease. Moreover, medicines and other therapies to control cell overgrowth are commonly used to treat multicentric Castleman disease. Treatment options vary depending on the severity of your illness and whether the patient has HIV, HHV-8, or both. Therefore, these agents do not only control symptoms short-term but continued administration to responders is safe and provides durable disease control. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global castleman disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of idiopathic multicentric Castleman disease (iMCD), well-established infrastructure, companies focusing on research & development and performing clinical trials and the presence of major players as well as government measures that aid medicine development for orphan diseases are some of the factors the market is expected to boost in the forecast period. For instance, it is estimated that 6500 to 7700 new cases are diagnosed each year in the United States; approximately 1000 of those are HHV-8-associated multicentric Castleman disease (HHV-8-associated MCD), and 1000 are HHV-8-negative MCD. Moreover, The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the castleman disease treatment market are EUSA Pharma, Johnson & Johnson Services, Inc., Genentech USA, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Par Pharmaceutical, Exela Pharma Sciences.

EUSA Pharma:

Overview:

EUSA Pharma was founded in March 2006. It is a newly-established, profitable specialty pharmaceutical company with global reach from its UK headquarters and commercial operations across Europe and the USA. It is focused on oncology and rare disease, continuously striving to confront gaps in patient care. EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America. It makes products available in approximately 40 countries worldwide through this broad international platform.

­Product Portfolio:

SYLVANT (siltuximab): It is the first and only FDA/EMA approved therapy for idiopathic Multicentric Castleman Disease (iMCD) and is recommended as the preferred first line therapy by clinical guidelines.

Why Purchase the Report?

Visualize the composition of the castleman disease treatment market segmentation by type, diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in castleman disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of castleman disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global castleman disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Diagnosis
  • 3.3. Market Snippet by Treatment
  • 3.4. Market Snippet by End user
  • 3.5. Market Snippet by Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Unicentric Castleman disease*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Multicentric Castleman disease

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 8.2. Blood and urine tests*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Imaging tests
    • 8.3.1. X-rays
    • 8.3.2. CT Scans
    • 8.3.3. Others
  • 8.4. Lymph node biopsy
  • 8.5. Others

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment Segment
  • 9.2. Immunotherapy*
    • 9.2.1. Siltuximab (Sylvant)
    • 9.2.2. Rituximab (Rituxan)
    • 9.2.3. Others
    • 9.2.4. Introduction
    • 9.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Chemotherapy
  • 9.4. Corticosteroids
    • 9.4.1. Prednisone
    • 9.4.2. Tocilizumab
    • 9.4.3. Lenalidomide
    • 9.4.4. Glucocorticoids
    • 9.4.5. Others
  • 9.5. Antiviral drugs
    • 9.5.1. Ganciclovir
    • 9.5.2. Others

10. By End user

    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Diagnostic Centers
  • 10.6. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. EUSA Pharma*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Johnson & Johnson Services, Inc.
  • 14.3. Genentech USA, Inc.
  • 14.4. F. Hoffmann-La Roche Ltd
  • 14.5. Amgen Inc.
  • 14.6. Bristol-Myers Squibb Company
  • 14.7. Par Pharmaceutical
  • 14.8. Exela Pharma Sciences

LIST NOT EXHAUSTIVE

15. Global Castleman Disease Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us